Emotional Disorder
Conditions
Keywords
emotional disorders, unified protocol, HiTOP, Hierarchical Taxonomy Of Psychopathology, transdiagnostic therapy, personality traits, temperamental traits
Brief summary
This randomised, parallel-group clinical trial evaluates the effects of the Unified Protocol (UP), a transdiagnostic cognitive-behavioural psychotherapy, on dimensional symptom outcomes aligned with the Hierarchical Taxonomy of Psychopathology (HiTOP) and on related temperamental/personality traits in adults with emotional disorders. Participants are randomly assigned (1:1:1) to UP, treatment as usual (TAU), or a waitlist (WL). Outcomes are assessed at baseline and after approximately 14 weeks. A planned follow-up assessment approximately 3 months after treatment completion is collected in the UP arm only.
Detailed description
This study is a single-site, randomised, parallel-group clinical trial conducted in routine outpatient care at the National Institute of Mental Health (NÚDZ), Czech Republic. The trial compares a manualised transdiagnostic cognitive-behavioural intervention (Unified Protocol; UP) with treatment as usual (TAU) and a waitlist (WL) condition in adults with emotional disorders. Participants are screened by telephone and diagnostic eligibility is confirmed using the ADIS-5 prior to randomisation. Randomisation is performed at the individual participant level (1:1:1) using a computer-based randomisation programme. Recruitment and enrolment occur on a rolling basis, contingent on clinical throughput and therapist availability. Assessments are completed at baseline (pre-randomisation) and at post-treatment (approximately 14 weeks) across all study arms. A planned follow-up assessment approximately 3 months after treatment completion is collected in the UP arm only; follow-up participation is voluntary and follow-up completion rates will be reported.
Interventions
BEHAVIORALUnified Protocol
Manualised transdiagnostic cognitive-behavioural psychotherapy delivered individually according to the Unified Protocol therapist manual. Treatment consists of approximately 14-16 sessions (about 60 minutes each) delivered over \~14 weeks in routine outpatient conditions.
BEHAVIORALTreatment as usual (TAU)
Routine outpatient psychotherapy provided as part of standard clinical care at NÚDZ. The psychotherapy modality may vary according to clinical indication and usual practice (e.g., psychodynamic/psychoanalytic/integrative). Treatment is delivered over approximately the same observation window (\~14 weeks).
Sponsors
National Institute of Mental Health, Czech Republic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label behavioural psychotherapy trial. Treatment assignment is not masked to participants or therapists. Questionnaire outcomes are self-reported and collected under pseudonymised study IDs; therapists do not have access to outcome datasets. The data analyst receives a de-identified dataset without direct identifiers.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adults aged 18-65 years. Seeking outpatient treatment at NÚDZ for emotional disorder symptoms. Meets diagnostic eligibility on ADIS-5 for at least one of the following (ICD-10 categories consistent with the protocol): F32, F33, F34, F40, F41, F42, F43, F45, F60, F61. Able to understand and complete study questionnaires and procedures (Czech language). Willing and able to participate in psychotherapy and complete assessments at baseline and post-treatment (14 weeks). If taking psychotropic medication: dose stable for ≥6 weeks prior to enrolment and expected to remain stable during the acute study period where clinically feasible. Provides written informed consent.
Exclusion criteria
Current or lifetime psychotic disorder or current manic/hypomanic episode. High acute suicide risk requiring a higher level of care (e.g., imminent risk, recent serious attempt) or current severe self-harm risk incompatible with outpatient psychotherapy study procedures. Primary substance use disorder requiring specialised treatment or acute intoxication/withdrawal. Severe cognitive impairment or neurodevelopmental/neurological condition that prevents valid consent or completion of study procedures. Concurrent psychological treatment that would conflict with study participation (e.g., starting a new structured psychotherapy during the 14-week study period), unless it constitutes the assigned TAU. Immediate need for intensive treatment (e.g., inpatient admission) at the time of screening. Inability to commit to the study schedule or complete required assessments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HiTOP-PRO Internalising Dimension Score | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | Self-reported internalising symptom severity measured with the HiTOP-PRO Internalising Dimension score. Primary analysis compares treatment groups on post-treatment Internalising score with baseline Internalising score as a covariate (ANCOVA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HiTOP-PRO Externalising Dimension Score | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | HiTOP-PRO Externalising Dimension score (dimensional externalising symptom severity) assessed by self-report questionnaire. |
| Depression Anxiety Stress Scales (DASS) | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | DASS self-report symptom severity (Depression, Anxiety, Stress subscales and/or total score per scoring procedures). |
| WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) Total Score | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | WHODAS 2.0 self-report disability/functioning total score |
| NEO Personality Inventory-Revised (NEO PI-R) Trait Scores | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | NEO PI-R personality trait domain scores (including Neuroticism and Extraversion; other domains per instrument scoring). |
| Behavioural Inhibition/Behavioural Activation System Scales (BIS/BAS) | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | BIS/BAS scale scores (behavioural inhibition and behavioural activation) assessed by self-report. |
| Client Satisfaction Questionnaire (CSQ-8) Total Score | Baseline (pre-randomisation) and post-treatment (approximately 14 weeks) | CSQ-8 total score assessing satisfaction with received psychotherapy (participants in UP or TAU arms). |
| HiTOP-PRO Internalising and Externalising Dimension Scores at Follow-up (UP Arm) | 3 months after post-treatment (UP arm only) | HiTOP-PRO Internalising and Externalising Dimension scores assessed in the Unified Protocol arm to examine maintenance of change; follow-up completion is voluntary. |
Countries
Czechia
Contacts
CONTACTEva Dreyfus, MSc.
Outcome results
None listed